Haleon PLC Sponsored ADR $HLN Shares Sold by Sculptor Capital LP

Sculptor Capital LP cut its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 49.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,300,868 shares of the company’s stock after selling 5,154,000 shares during the quarter. Sculptor Capital LP’s holdings in Haleon were worth $53,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HLN. Third View Private Wealth LLC purchased a new stake in shares of Haleon during the 4th quarter worth $3,461,000. Scharf Investments LLC increased its holdings in shares of Haleon by 17.4% in the 4th quarter. Scharf Investments LLC now owns 1,095,734 shares of the company’s stock valued at $11,078,000 after purchasing an additional 162,406 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in shares of Haleon by 9.1% in the fourth quarter. First Eagle Investment Management LLC now owns 3,335,583 shares of the company’s stock valued at $33,723,000 after purchasing an additional 278,632 shares during the period. SG Americas Securities LLC lifted its stake in shares of Haleon by 1,721.7% in the fourth quarter. SG Americas Securities LLC now owns 521,539 shares of the company’s stock valued at $5,273,000 after purchasing an additional 492,910 shares during the period. Finally, Goodman Financial Corp acquired a new stake in shares of Haleon in the first quarter valued at about $11,488,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.2%

NYSE:HLN opened at $9.79 on Monday. The company has a market capitalization of $43.14 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.26 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 52-week low of $8.65 and a 52-week high of $11.28. The stock has a fifty day simple moving average of $9.36 and a 200-day simple moving average of $9.85.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Rothschild & Co Redburn lowered Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Haleon presently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.